1 / 21 | 目录 | | --- | 2018 年第三季度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2018 年第三季度报告 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 10 | 2018 年第三季度报告 一、 重要提示 2.1 主要财务数据 3 / 21 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司董事长杨国占、总经理周晓冰、总会计师、财务负责人王立鑫及财务部部长李建军保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 单位：元 币种：人民币 4 / 21 | 润 | | | | | | --- | --- | --- | --- | --- | | 加权平均净资产 收益率（%） | 1.44 | 0.41 | 增加 1 ...

2018 年半年度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2018 年半年度报告 2018 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 报告期内，公司无半年度利润分配预案或资本公积金转增股本预案。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告内容中涉及的未来计划等前瞻性陈述因存在不确定性，不构成公司对投资者的实质承 诺，请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 1 / 154 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细 阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查阅第四节经营情况讨论与分 析中"可能面对的风险"部分。 十、 其他 □适用 √不适用 2 / 154 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本 ...

Financial Performance - The company's operating revenue for 2017 was CNY 7,709,121,876.65, a decrease of 4.62% compared to CNY 8,082,462,780.74 in 2016[21] - The net profit attributable to shareholders for 2017 was CNY 18,759,714.59, down 65.52% from CNY 54,415,076.90 in 2016[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 21,952,245.00, compared to a loss of CNY 51,225,930.49 in 2016[21] - The net cash flow from operating activities for 2017 was CNY 287,250,352.97, a significant recovery from a negative cash flow of CNY 446,526,268.32 in 2016[21] - As of the end of 2017, the total assets of the company were CNY 17,151,500,181.55, an increase of 4.10% from CNY 16,476,254,037.09 at the end of 2016[21] - The net assets attributable to shareholders at the end of 2017 were CNY 5,306,362,379.92, a slight decrease of 0.12% from CNY 5,312,746,741.08 in 2016[21] - Basic earnings per share decreased by 63.64% to CNY 0.012 in 2017 from CNY 0.033 in 2016[22] - Diluted earnings per share also decreased by 63.64% to CNY 0.012 in 2017 from CNY 0.033 in 2016[22] - The total profit for the year was 59.55 million RMB, a decrease of 23.79% compared to the previous year, which is a reduction of 18.59 million RMB[51] Revenue and Sales Growth - Total revenue for the year was CNY 8,708,111,876.65, with Q4 revenue reaching CNY 2,010,847,769.51[24] - In 2017, the company achieved a year-on-year revenue growth of over 20% for 65 formulation products, with 10 products generating over 100 million yuan in revenue[42] - The sales revenue of the company's biological products doubled year-on-year, with hepatitis B vaccine revenue reaching nearly 500 million yuan[42] - The company achieved total revenue of 7.709 billion RMB in 2017, with pharmaceutical and chemical revenue at 6.577 billion RMB, representing a year-on-year growth of 13.62%[51] - The company launched 10 products with over 100 million RMB in revenue, and 65 product varieties saw revenue growth of over 20%[52] Market and Industry Trends - The pharmaceutical manufacturing industry saw a 12.4% increase in value added in 2017, with a 12.2% increase in main business income[35] - Chemical drug preparation industry achieved a 12.9% increase in main business income, reaching CNY 8,340.6 billion in 2017[36] - The biopharmaceutical industry in China had a market size of ¥129.8 billion in 2016, accounting for 9.0% of the domestic pharmaceutical market[81] - The global biopharmaceutical industry has maintained a sales growth rate of 15% to 33% for over a decade, significantly outpacing the average economic growth rate[81] - The cardiovascular drug market in China is expected to continue stable growth due to the rising incidence of cardiovascular diseases, driven by the aging population[82] Research and Development - Research and development expenses increased by 8.90% to 174.14 million RMB, with 27 patents authorized, including 23 invention patents[53] - The company’s R&D investment totaled CNY 174.14 million, accounting for 2.26% of operating revenue, which is in line with the industry average[71] - The company has established a comprehensive R&D system, including a national key laboratory for antibody drug development and a national engineering research center for microbial drugs[122] - The company is focusing on the development of its antibiotic and biopharmaceutical product lines to enhance its market position amid industry challenges[79][80] - The company is actively pursuing new product development to meet clinical needs and enhance market competitiveness, particularly in the context of rising R&D costs and evolving policies[98] Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[7] - The company has outlined various risks and countermeasures in the report, indicating a proactive approach to risk management[7] - The company is facing significant risks due to a complex pharmaceutical environment, including rising costs of raw materials, energy, and labor, as well as tightening financing conditions[165] - The company aims to improve its internal management and risk control systems, including optimizing its financing structure and enhancing its talent management system[164] Corporate Governance and Compliance - The company did not engage in any non-operating fund occupation by controlling shareholders or related parties[7] - The company has not reported any significant accounting errors or non-standard audit opinions during the reporting period[178] - The company has not engaged in any significant related party transactions that would affect its financial performance[176] - The company has committed to not occupy company funds or require the company to advance expenses such as wages and insurance, ensuring financial integrity[176] Environmental and Social Responsibility - The company has implemented an environmental management system and achieved ISO14001 certification, emphasizing its commitment to environmental protection[198] - The company has established a social responsibility management system, ensuring compliance with international standards and national laws[197] - The company has been recognized as one of the "most socially responsible enterprises" in a national survey conducted by the National Health and Family Planning Commission[197] Future Outlook and Strategic Plans - The company plans to enhance its product structure by focusing on high-value biopharmaceuticals and introducing non-antibiotic first-generic products[161] - The company aims to achieve a revenue target of 9.8 billion yuan in 2018, with 8.3 billion yuan from pharmaceutical chemicals and a total profit of 165 million yuan[160] - The company is focusing on expanding its market share in formulation products and enhancing its international competitiveness through unified management of exports[47] - The company plans to invest in research and development, with a budget allocation of 42,138.17 million for innovative drug formulations[120]

2018 年第一季度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2018 年第一季度报告 1 / 19 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司副董事长（主持工作）、总经理刘文富，总会计师、财务负责人王立鑫及财务部部长李 建军保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 2018 年第一季度报告 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | 698,819.37 | | | 计入当期损益的政府补助，但与公 司正常 ...

2017 年第三季度报告 1 / 23 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2017 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2017 年第三季度报告 1.3 公司副董事长（主持工作）、总经理刘文富、总会计师、财务负责人王立鑫及财务部部长李 建军声明：保证季度报告中财务报表的真实、准确、完整。 注：公司原董事长郭周克已于 2017 年 2 月 9 日辞职，不再担任公司任何职务，现由公司副董事长、总经理刘 文富主持工作。（详见公司临 2017-005 公告。） 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 23 单位：元 币种：人民币 ...

Financial Performance - The company's operating revenue for the first half of 2017 was ¥4,003,315,532.84, representing a 1.12% increase compared to ¥3,959,061,852.59 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥30,791,994.37, up 2.23% from ¥30,118,842.58 in the previous year[21]. - The net cash flow from operating activities was ¥24,138,771.65, a significant recovery from a negative cash flow of ¥309,870,824.64 in the same period last year[21]. - The total assets at the end of the reporting period were ¥16,807,548,268.91, an increase of 2.01% from ¥16,476,254,037.09 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were ¥5,319,887,210.69, showing a slight increase of 0.13% from ¥5,312,746,741.08 at the end of the previous year[21]. - Basic earnings per share for the first half of 2017 were ¥0.019, a 5.56% increase from ¥0.018 in the same period last year[22]. - The weighted average return on net assets was 0.58%, slightly up from 0.57% in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥17,109,061.70, down 20.88% from ¥21,623,236.51 in the same period last year[21]. - The company did not propose any profit distribution plan or capital reserve transfer to share capital during the reporting period[4]. Industry Overview - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of nearly 700 products, including antibiotics, cardiovascular drugs, and tumor treatment drugs[26]. - In the first half of 2017, the pharmaceutical manufacturing industry achieved a total revenue of CNY 15,314.4 billion, with a year-on-year growth of 12.4%[30]. - The chemical pharmaceutical industry generated a revenue of CNY 6,682.5 billion in the first half of 2017, reflecting a year-on-year increase of 11.1%[31]. - The pharmaceutical industry in China is projected to reach CNY 28,350 billion in sales by 2017, with a compound annual growth rate of approximately 6.52% from 2017 to 2021[32]. Company Position and Strategy - The company is recognized as one of the largest chemical pharmaceutical enterprises in China, with total assets exceeding CNY 15 billion and annual sales nearing CNY 10 billion[36]. - The company has a strong market position in the antibiotic sector, with a complete product chain from raw materials to formulations, leading in production scale and product quality domestically[37]. - The biopharmaceutical sector is a key focus, with the company being one of the earliest entrants and holding a national key laboratory for antibody drug research[37]. - The company’s logistics operations leverage its supply chain advantages, providing services that include warehousing, transportation, and distribution, contributing to overall revenue[30]. - The company has received multiple accolades, including being named a "Meritorious Enterprise in the Pharmaceutical Industry" and "Top 100 Comprehensive Strength Enterprises in the Chemical Pharmaceutical Industry" in 2016[36]. Research and Development - Research and development expenditure rose by 19.48% to CNY 76.10 million, reflecting increased investment in innovation[50]. - The company has obtained 14 patents in the first half of the year, including 11 invention patents[48]. - The company is advancing the construction of a biopharmaceutical industrialization base project, focusing on high-value therapeutic areas[45]. Financial Health and Liabilities - The company's total liabilities increased by 4.60% to 16,000,000,000.00 CNY, with a significant rise in short-term borrowings[53]. - The company's short-term borrowings increased by 43.62% to 5,026,322,195.78 CNY, reflecting adjustments in financing structure[53]. - The company reported a net profit of -12,427,208.01 CNY, a decrease of 17.20% compared to the previous period[54]. - The revenue from the subsidiary Hebei Huamin Pharmaceutical decreased by 9.56% to 794,750,000 CNY, with a net profit of -84,997,676.80 CNY[57]. Environmental Management - The company has implemented an environmental management system and passed the ISO14001 certification, focusing on reducing environmental risks[78]. - The company has developed a complete set of technology for harmless disposal and resource utilization of antibiotic residues, achieving domestic leading standards[78]. - The company has established a comprehensive internal environmental management system to monitor and reduce VOC emissions[78]. Shareholder Information - As of the end of the reporting period, the total number of common stock shareholders was 88,820, with no preferred shareholders regaining voting rights[89]. - The top shareholder, Jizhong Energy Group Co., Ltd., holds 352,227,171 shares, representing 21.60% of the total shares[91]. - There were no changes in the number of shares held by the top ten shareholders during the reporting period[91]. Legal and Compliance - There are no major lawsuits or arbitration matters reported during the period, indicating a stable legal standing[69]. - The company has not engaged in any significant asset acquisitions or disposals during the reporting period[72]. - The company has committed to not engaging in related party transactions that violate regulations and will ensure fair pricing in such transactions[66]. Accounting and Financial Reporting - The financial report was approved by the board on August 10, 2017, ensuring compliance with accounting standards[144]. - The financial statements are prepared based on the accrual basis of accounting, reflecting the company's financial position accurately[146]. - The company has not reported any changes in accounting policies or prior period error corrections during the current reporting period[136].

2017 年第一季度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2017 年第一季度报告 1 / 18 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 8 | 2017 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元币种：人民币 | | | 3 / 18 单位：元币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 17,089,034,509.09 16,476,254,037.09 3.72 归属于上市公司 股东的净资产 5,336,308,230.38 5,312,746,741.08 0.44 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的 现金流量净额 8,980,868.54 10,011,635.98 -10.3 年初至报告期末 上年初至上年报告期末 比上年同期增减（%） 营业收入 2,161,125,855.73 ...

2016 年年度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2016 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 中天运会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司副董事长（主持工作）、总经理刘文富、总会计师、财务负责人王立鑫及财务部部长李 建军声明：保证年度报告中财务报告的真实、准确、完整。 注：公司原董事长郭周克已于 2017 年 2 月 9 日辞职，不再担任公司任何职务，现由公司副董事长、总经理刘 文富主持工作。（详见公司临 2017-005 公告。） 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2016年度利润分配预案如下: 1、以 2016 年末公司总股本1,630,804,729股为基数，以现金股利方式向全体股东派发红利 人民币32,616,094.58元，即每 10 股分配现金红利0.20元，剩余未分配利润人民币 1,068,746,795. ...

2016 年第三季度报告 公司代码：600812 公司简称：华北制药 华北制药股份有限公司 2016 年第三季度报告 1 / 27 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 13 | 2016 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司副董事长、总经理刘文富、总会计师、财务负责人王立鑫及财务部部长李建军保证季度 报告中财务报表的真实、准确、完整。 注：公司董事长杨海静先生由于工作原因已辞去公司董事长、董事职务，暂由公司副董事长刘文富先生主持 工作（详见公司临 2016-067 公告） 1.4 本公司第三季度报告未经审计。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度 ...

Financial Performance - The company's operating revenue for the first half of 2016 was CNY 3,959,061,852.59, a decrease of 12.00% compared to CNY 4,498,757,111.87 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 30,118,842.58, down 12.62% from CNY 34,467,152.64 year-on-year[19]. - The net cash flow from operating activities was negative at CNY -309,870,824.64, a decline of 330.19% compared to CNY 134,613,836.90 in the previous year[19]. - The total profit amounted to CNY 35.1738 million, representing a year-on-year growth of 7.17%[25]. - The company reported a net profit of -55,999,027.62 CNY for Hebei Huamin Pharmaceutical Co., Ltd., with total assets of 5,278,305,148.75 CNY and net assets of 1,162,037,160.20 CNY[49]. - The company reported a net loss of CNY 15.05 million, compared to a loss of CNY 12.56 million in the previous period[90]. - The total comprehensive income for the first half of 2016 was CNY 30,079,910.14, compared to CNY 23,124,467.93 in the same period last year, reflecting an increase of 30.0%[100]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 16,325,801,660.35, an increase of 2.05% from CNY 15,997,230,054.09 at the end of the previous year[19]. - The company’s long-term liabilities increased significantly, with current liabilities reaching CNY 1.768 billion, reflecting adjustments in financing structure[31]. - The total current assets as of June 30, 2016, amounted to RMB 6,749,752,355.87, an increase from RMB 6,514,339,999.71 at the beginning of the period, reflecting a growth of approximately 3.62%[88]. - Total liabilities reached CNY 11.06 billion, compared to CNY 10.73 billion, reflecting a growth of approximately 3.1%[90]. - The total amount of guarantees provided by the company, including those to subsidiaries, is 89,100.00 million[65]. Revenue and Cost Management - The total operating revenue for the company was CNY 3,927,364,098.35, a decrease of 11.43% compared to the previous year[40]. - The gross profit margin for the chemical raw materials segment was 6.69%, down by 5.81 percentage points year-on-year, while the chemical preparations segment saw a gross profit margin of 32.4%, an increase of 5.45 percentage points[36]. - The revenue from biopharmaceuticals reached CNY 123,553,052.19, with a gross profit margin of 72.67%, reflecting an increase of 11.61 percentage points year-on-year[37]. - The revenue from the domestic market was CNY 3,357,332,791.49, representing a decline of 13.08% compared to the previous year[40]. - The company successfully reduced sales expenses by 3.66% to CNY 348.36 million due to a decrease in revenue[30]. Strategic Initiatives and Future Outlook - The company plans to continue its strategic reforms and product structure optimization in the second half of the year to meet annual targets[34]. - The company aims to enhance its product offerings in new therapeutic areas such as cardiovascular, oncology, kidney disease, and diabetes[45]. - The company is focusing on market expansion and new product development as part of its growth strategy[96]. - Future guidance indicates a cautious outlook due to market conditions, with emphasis on cost management and efficiency improvements[96]. Research and Development - The company applied for 14 patents and was granted 18, including 16 invention patents, indicating a strong focus on innovation[27]. - The company has established a national engineering research center for microbial drugs, indicating a strong R&D advantage in the pharmaceutical sector[41]. Shareholder Information - The total number of shareholders reached 92,875 by the end of the reporting period[77]. - Jizhong Energy Group holds 602,227,171 shares, accounting for 36.93% of total shares, with 175,000,000 shares pledged[78]. - The company reported a total of 252,227,171 shares under limited sale conditions, which will become tradable on April 9, 2017[80]. Compliance and Governance - The company is committed to complying with relevant laws and regulations in its operations[72]. - The company has established sound internal controls and financial accounting systems[72]. - The company has not indicated any changes in its controlling shareholder or actual controller during the reporting period[81]. Financial Reporting and Accounting Policies - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations for the next 12 months[124]. - The company has not experienced any changes in its total share capital or structure during the reporting period[74]. - There are no significant changes in the company's accounting policies or estimates[73].